| Budget Amount *help |
¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Outline of Final Research Achievements |
We have developed new adjuvants useful in vaccine therapy for cancer patients, and we searched the usefulness of HVJ-E, which co-stimulate the RIG-I / TLR-8, as one of the candidates for an adjuvant to enhance the effect of cancer peptide vaccine. It was revealed that the HVJ-E induced the production of inflammatory cytokines such as IL-17, IFN, IL-6 and TNF through the maturation and activation of dendritic cells. On the other hand, producing these cytokines in the systemic was suggested to inhibit the anti-tumor immune responses. In addition, we have started a new clinical study of peptides vaccine for the patients of esophageal cancer. So far, 22 patients were enrolled and we have started immunologic assessment of peptide-specific activated CTL (ELISPOT testing, multimer assay). By storing this new but basic data, we are preparing to initiate a next clinical study of cancer peptides vaccine in combination with a novel immune adjuvant.
|
